AzurRx BioPharma Inc (NASDAQ:AZRX) dropped 10.7% during mid-day trading on Tuesday . The company traded as low as $1.02 and last traded at $1.09, approximately 679,230 shares traded hands during mid-day trading. An increase of 523% from the average daily volume of 109,060 shares. The stock had previously closed at $1.22.
AZRX has been the subject of a number of recent research reports. National Securities initiated coverage on shares of AzurRx BioPharma in a report on Tuesday, June 11th. They issued a “buy” rating and a $9.00 price objective for the company. Maxim Group reissued a “buy” rating and issued a $315.00 price objective (up previously from $305.00) on shares of Domino’s Pizza in a report on Wednesday, April 24th. Finally, HC Wainwright set a $3.00 price objective on shares of McEwen Mining and gave the company a “buy” rating in a report on Friday, May 24th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $7.58.
The firm has a market capitalization of $23.80 million, a PE ratio of -1.24 and a beta of 2.24. The stock’s fifty day moving average price is $1.71.
Several institutional investors have recently modified their holdings of AZRX. 683 Capital Management LLC lifted its holdings in shares of AzurRx BioPharma by 73.9% during the 4th quarter. 683 Capital Management LLC now owns 695,504 shares of the company’s stock worth $842,000 after acquiring an additional 295,504 shares during the period. Waldron Private Wealth LLC bought a new stake in shares of AzurRx BioPharma during the 1st quarter worth approximately $169,000. Finally, Regentatlantic Capital LLC bought a new stake in shares of AzurRx BioPharma during the 1st quarter worth approximately $48,000. 13.12% of the stock is owned by institutional investors.
AzurRx BioPharma Company Profile (NASDAQ:AZRX)
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Featured Story: The basics of gap trading strategies
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.